Compugen Ltd. (CGEN) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Compugen Ltd. (NASDAQ:CGEN) from a hold rating to a sell rating in a research report sent to investors on Monday, May 22nd.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, FBR & Co reaffirmed a buy rating on shares of Compugen in a research note on Saturday, March 4th.

Compugen (NASDAQ:CGEN) remained flat at $3.70 during mid-day trading on Monday. 172,717 shares of the company were exchanged. The company’s market cap is $189.18 million. The company’s 50 day moving average is $4.28 and its 200-day moving average is $4.65. Compugen has a 12 month low of $3.55 and a 12 month high of $7.57.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.01. Compugen had a negative return on equity of 47.40% and a negative net margin of 4,425.00%. Equities research analysts predict that Compugen will post ($0.69) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Compugen Ltd. (CGEN) Rating Lowered to Sell at Zacks Investment Research” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/06/16/compugen-ltd-cgen-downgraded-by-zacks-investment-research-updated-updated.html.

A number of institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in shares of Compugen by 522.2% in the first quarter. Tower Research Capital LLC TRC now owns 23,576 shares of the biotechnology company’s stock worth $101,000 after buying an additional 19,787 shares during the period. Geode Capital Management LLC boosted its position in shares of Compugen by 3.1% in the first quarter. Geode Capital Management LLC now owns 29,978 shares of the biotechnology company’s stock worth $128,000 after buying an additional 888 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Compugen by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 59,797 shares of the biotechnology company’s stock worth $257,000 after buying an additional 16,696 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in shares of Compugen by 5.7% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 66,300 shares of the biotechnology company’s stock worth $285,000 after buying an additional 3,600 shares during the period. Finally, Vident Investment Advisory LLC boosted its position in shares of Compugen by 22.2% in the fourth quarter. Vident Investment Advisory LLC now owns 125,514 shares of the biotechnology company’s stock worth $640,000 after buying an additional 22,820 shares during the period. 19.40% of the stock is currently owned by institutional investors and hedge funds.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply